Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare Biotechnology
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel

GlobeNewswire March 19, 2018

Collegium to Present at Upcoming Investor Conferences

GlobeNewswire March 16, 2018

Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update

GlobeNewswire March 7, 2018

Collegium Pharmaceutical, Inc. to Host Earnings Call

Accesswire March 7, 2018

A Preview Of Collegium Pharmaceutical Q4 Earnings

Benzinga.com  March 7, 2018

Collegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update

GlobeNewswire February 26, 2018

Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise

GlobeNewswire January 10, 2018

Collegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference

GlobeNewswire December 12, 2017

Collegium to License Rights to Commercialize Nucynta Franchise

GlobeNewswire December 4, 2017

Collegium to Present at the 29th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 22, 2017

Collegium Reports Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2017

Collegium Pharmaceutical, Inc. to Host Earnings Call

Accesswire November 8, 2017

Collegium Receives FDA Approval for sNDA for Xtampza® ER

GlobeNewswire November 7, 2017

Collegium Notified that the FDA Will Not Meet PDUFA Goal Date for sNDA for Xtampza® ER

GlobeNewswire November 6, 2017

Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

Benzinga.com  October 31, 2017

Collegium to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update

GlobeNewswire October 30, 2017

Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma, and Collegium Pharma

PR Newswire October 30, 2017

Collegium to Present at Upcoming Investor Conferences

GlobeNewswire September 6, 2017

Collegium Announces Scientific Presentations at PAINWeek 2017 Meeting

GlobeNewswire September 5, 2017

Daily Technical Summary Reports on Generic Drugs Stocks -- Collegium Pharma, Momenta Pharma, Lipocine, and Diplomat Pharma

PR Newswire August 23, 2017